Chuan-Liang Cui

Peking University, Peping, Beijing, China

Are you Chuan-Liang Cui?

Claim your profile

Publications (5)4.09 Total impact

  • [Show abstract] [Hide abstract] ABSTRACT: To study the expression and prognostic significance of galectin-1 and galectin-3 in different melanocytic lesions. The expression of galectin-1 and galectin-3 in 39 cases of benign nevus, 58 cases of primary cutaneous melanoma, 24 cases of primary mucosal melanoma, 69 cases of melanoma with lymph node metastasis and 8 cases of melanoma with distant metastasis were studied by immunohistochemistry and tissue microarray. The expression of galectin-1 and galectin-3 was higher in benign nevi than in melanomas (P < 0.01). The nuclear expression of galectin-3 was higher in primary cutaneous melanomas than in primary mucosal melanomas or melanomas with metastases (P < 0.01, respectively). The expression correlated with age of patients (P < 0.05), necrosis (P < 0.05) and survival time (P < 0.01). Clark's level also correlated with survival time in patients with cutaneous melanomas (P = 0.037). TNM staging was the only independent prognostic factor for melanomas (P < 0.01). The expression of galectin-1 and galectin-3 is decreased in melanomas. The decrease in nuclear expression of galectin-3 may represent a poor prognostic factor for melanomas. TNM staging is an independent prognostic factor which influences the survival time.
    No preview · Article · Dec 2013 · Zhonghua bing li xue za zhi Chinese journal of pathology
  • Yan Wang · Wei-cheng Xue · Lu Si · Chuan-liang Cui · Ai-ping Lu · Deng-feng Cao · Jun Guo · Zhong-wu Li
    [Show abstract] [Hide abstract] ABSTRACT: To investigate the correlations among Ki-67 expression, mitosis and other clinicopathological parameters of primary cutaneous malignant melanoma, and search for prognostic factors of malignant melanoma. Totally 127 cases of primary cutaneous malignant melanoma were collected from Beijing Cancer Hospital. Immunohistochemical study for Ki-67 was performed, and the mitosis was calculated referring to "hot spot" method recommended by the seventh edition of the American Joint Committee on Cancer (AJCC) melanoma staging system. The correlations of Ki-67 expression, mitosis and other clinicopathological parameters were analyzed, and the survival analysis of all these risk factors including TNM and Clark level was conducted based on follow up data. The expression level of Ki-67 was associated with necrosis and Breslow thickness (P < 0.05). Mitosis was correlated with Clark level and Ki-67 expression (P < 0.05). Univariate analysis indicated Ki-67 expression level (P = 0.043), mitosis (P = 0.030) and TNM stage (P < 0.001) might influence the survival of patients. However, multivariate analysis showed that the TNM staging was the only independent prognostic factor affecting survival. The prognosis of patients with primary cutaneous malignant melanoma was closely related to the TNM staging at the fist examination. Ki-67 expression and mitosis are two important clinicopathological parameters of primary cutaneous malignant melanoma.
    No preview · Article · Mar 2013 · Zhonghua bing li xue za zhi Chinese journal of pathology
  • Shao-Yu Yang · Chuan-Liang Cui · Zhi-Hong Chi · Lu Si · Xi-Nan Sheng · Li-Li Mao · Bin Lian · Jun Guo
    [Show abstract] [Hide abstract] ABSTRACT: Objective: To evaluate the safety and efficacy of sorafenib plus cisplatin in the treatment of metastatic renal cell carcinoma (mRCC) with pleural effusion. Methods: A total of 30 patients with mRCC (clear cell carcinoma) with pleural effusion from April 2009 to January 2011 were recruited. All received sorafenib 400 mg twice daily. And 11 patients in chemotherapy group received sorafenib plus local chemotherapeutic perfusion of cisplatin 40 mg weekly for 2 weeks while another 19 patients in control group received sorafenib alone. Results: The response rate of pleural effusion was 10/11 for chemotherapy group versus 3/19 for control group (χ(2) = 13.097, P < 0.01). Followed up to April 30(th), 2011, 5 of 11 patients in chemotherapy group and 10 of 19 patients in control group died. Among those on sorafenib, the median overall survival time was 22 months (95%CI: 2.12 - 41.88) for local chemotherapy versus 9 months (95%CI: 8.20 - 9.80) without local therapy (P = 0.04). The most common events in local chemotherapy group were I-II thoracic pain, nausea and vomiting. And the incidence rates were 8/11 and 9/11 versus 4/19 and 3/19 respectively (P < 0.01). The main laboratory abnormalities were similar in two groups. Conclusion: The regimen of sorafenib plus pleural cavity perfusion of cisplatin is both effective and safe in the treatment of mRCC with pleural effusion. It may control local symptoms and achieve a better overall survival.
    No preview · Article · Nov 2012 · Zhonghua yi xue za zhi
  • Lu Si · Zhi-hong Chi · Xiang-qing Yuan · Chuan-liang Cui · Xi-nan Sheng · Jun Guo
    [Show abstract] [Hide abstract] ABSTRACT: Objective To investigate fotemustine plus dacarbazine (DTIC) with dendritic cell (DC) vaccines on patients with advanced acral lentiginous melanoma (ALM). Fotemustine is a cytotoxic alkylating agent with a remarkable antitumor activity as single agent but also in association with (DTIC). DC is the strongest antigen presenting cell which could induce durable clinical responses. Methods This was a single-center study. Between July 2003 and June 2006, twenty-eight chemotherapy-naive patients of advanced ALM received fotemustine 100 mg/m2, d1, 12, DTIC 400 mg/d d2–6, DC vaccines subcutaneously d7, 9, 13 repeated every 28 days. Ten HLA-A02+24+ patients received vaccines pulsed with melanoma antigen derived peptides, melanoma antigen recognized by T-cells 1 (Mart-1) and S-100. Eighteen patients received DC loaded with allogeneic melanoma lysate. The primary end-point was progression free survival (PFS). Secondary end-points were overall survival (OS), overall response rate (ORR) and toxicity. Tumor assessment was performed every 8 weeks and evaluated according to response evaluation criteria in solid tumors (RECIST). Results The 15 men and 13 women had a median age of 51 years. 16 patients had stage M1c disease and 11/16 had liver metastasis. Patients received an average of 3.82±1.25 cycles. Follow-up for the 18 surviving patients ranged from 7–41 months with a median of 12 months. Median PFS was 8.5 months (95% CI: 7.86–15.21) with 12 patients remaining progression free. Only 10 patients died. Median OS was 12 months (95% CI: 10.33–18.24). ORR (CR+PR) was 35.7% including 3 complete response (CR) and 7 partial response (PR). Six patients had disease stable. A total of 19 Grade III/IV toxicities were observed including thrombocytopenia (n=8), neutropenia (n=5), fatigue (n=6) and hypersensitivity reaction (n=1). One patient died of Grade IV thrombocytopenia. Conclusion Fotemustine and dacarbazine plus DC vaccines are safe and tolerable to Chinese ALM patients. The regimen brings clinical benefit with a higher ORR and may provide a survival advantage. Updated survival data will be presented.
    No preview · Article · Jan 2009 · Chinese Journal of Cancer Research
  • Source
    Chuan-Liang Cui · Zhi-Hong Chi · Xiang-Qing Yuan · Hong-Yun Lian · Lu Si · Jun Guo
    [Show abstract] [Hide abstract] ABSTRACT: The therapeutic effect on melanoma metastasizing to liver is poor. Researches have demonstrated that hepatic intra-arterial bio-chemotherapy can improve the treatment efficacy of metastatic melanoma. This study was to investigate hepatic intra-arterial bio-chemotherapy for the treatment and survival of patients with liver metastasis from melanoma. Twenty-one patients with liver metastasis from melanoma were treated with hepatic intra-arterial infusion of dacarbazine (250 mg/m(2)) from the first to the fifth day, and fotemustine (100 mg/m(2)) at the sixth and fourteenth day, followed by adoptive transfer of autologous cytokine-induced killer cells and administration of interleukin-2 and 150 ug granulocyte/macrophage colony stimulating factor for 10-12 days. The treatment was repeated every 28 days. The overall survival, response and toxicity were analyzed. Seventeen of twenty-one patients were evaluable. One achieved complete remission (CR), one achieved partial remission (PR), six had stable disease (SD) and nine had progression disease (PD).The disease control rate was 47.06% (8/17), with a median progression free survival (PFS) of 3.76 months and a medium overall survival (OS) of 6 months. Treatment related complications were mainly myelosuppression (grade III-IV), occurring in 38.1% (8/21) patients. Hepatic intra-arterial chemotherapy can improve the disease control rate of progressive melanoma. It tends to prolong the PFS and OS with tolerable toxicity in patients with liver metastasis from melanoma.
    Preview · Article · Aug 2008 · Ai zheng = Aizheng = Chinese journal of cancer